Hierarchical classification according to cytogenetic and molecular abnormalities defined in the WHO 2022 classification of AML9 showed that IKZF1N159mut AML largely lacks subgroup‐defining genetic lesions, such as characteristic fusion genes or bZIP in‐frame CEBPA mutations (Figure 1E). Here, CEBPA is linked to acute myeloid leukemia.